NAD Supplementation to Prevent Progressive Neurological Disease in Ataxia Telangiectasia

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

June 5, 2019

Primary Completion Date

September 3, 2024

Study Completion Date

June 16, 2027

Conditions
Ataxia Telangiectasia
Interventions
DRUG

Nicotinamide ribonucleoside

Two year intervention

Trial Locations (2)

Unknown

Hilde Loge Nilsen, Lørenskog

Oslo University Hospital, Oslo

All Listed Sponsors
collaborator

The Bergesen Foundation

OTHER

collaborator

South-Eastern Norway Regional Health Authority

OTHER

collaborator

Sykehuset Innlandet HF

OTHER

collaborator

Oslo University Hospital

OTHER

collaborator

St. Olavs Hospital

OTHER

collaborator

Haukeland University Hospital

OTHER

collaborator

University Hospital of North Norway

OTHER

collaborator

University of Bergen

OTHER

lead

University Hospital, Akershus

OTHER